New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2013
07:14 EDTSPNCFinal results of Spectranetics study supports successful laser atherectomy use
Spectranetics announced final results from the Photo-Ablation using the Turbo-Booster and Excimer Laser for In-Stent Restenosis Treatment, or PATENT, study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis, or ISR, in the femoropopliteal artery in the leg. ISR occurs as a result of narrowing of the artery in patients who have undergone stenting for the treatment of peripheral arterial disease, or PAD. There is currently no FDA-cleared or approved device to treat peripheral in-stent restenosis, which remains a major unsolved medical problem. Ninety patients participated in this prospective, multi-center registry, which completed enrollment in December 2011 at five centers in Germany. The study evaluated extremely complex patients who had a previously failed stent procedure to address peripheral arterial disease. Final results presented indicate 82% and 52% freedom from target lesion revascularization, or TLR, at six and 12 months, respectively. Laser atherectomy demonstrated excellent midterm primary patency of 64% as compared to 37% with balloon angioplasty primary patency as published in previous clinical registries. This is a significant improvement considering the challenging nature of these patients.
News For SPNC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
08:28 EDTSPNCSpectranetics has a conference call hosted by JPMorgan
Subscribe for More Information
May 21, 2015
08:34 EDTSPNCSpectranetics management to meet with Piper Jaffray
Meeting to be held in Southern California on May 21 hosted by Piper Jaffray.
May 13, 2015
07:31 EDTSPNCHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use